Immunogenicity of meningococcal B polysaccharide conjugated to tetanus toxoid or CRM197 via adipic acid dihydrazide

Vaccine
A BartoloniP Costantino

Abstract

Vaccine development against Group B Neisseria meningitidis is complicated by the nature of the capsular polysaccharide, which is alpha 2-8-linked poly-sialic acid, identical in structure to the poly-sialic acid found in many mammalian tissues during development. To test the feasibility of a vaccine based on this polysaccharide, we synthesized several conjugates of meningococcal B polysaccharide linked to a carrier protein (tetanus toxoid or diphtheria CRM197), via an adipic acid dihydrazide (ADH) spacer. All conjugates induced a strong immune response. However, most of the antibodies were not directed against the Meningococcus B polysaccharide and could not be inhibited by the purified polysaccharide alone. Further investigations showed that the antibodies recognized an epitope composed by the junction between the spacer and the polysaccharide and protein, that is not present in the native polysaccharide and is generated during the coupling reaction. This epitope becomes immunodominant with respect to the poorly immunogenic polysaccharide. While the majority of the immune response is directed against the above epitope, the conjugates induced also an immune response against the Meningococcus B polysaccharide. The anti-Meningococ...Continue Reading

References

May 1, 1990·The Journal of Infectious Diseases·J B Robbins, R Schneerson
Oct 10, 1985·Journal of Immunological Methods·A SuttonR Schneerson
Sep 1, 1972·Immunochemistry·A M PappenheimerA A Harper
Nov 1, 1972·The Journal of Infectious Diseases·F A WyleJ P Lowenthal
Apr 29, 1983·Biochemical and Biophysical Research Communications·J FinneC Goridis

❮ Previous
Next ❯

Citations

Dec 12, 2001·Vaccine·S L Morley, A J Pollard
Apr 13, 1999·Infectious Disease Clinics of North America·H Ahmad, E K Chapnick
Sep 2, 1999·Infectious Disease Clinics of North America·H Peltola
Feb 1, 1997·Zentralblatt Für Bakteriologie : International Journal of Medical Microbiology·J D Romero, I M Outschoorn
Feb 13, 2003·Drug Discovery Today·A Christy Hunter, S Moein Moghimi
Aug 10, 2000·Scandinavian Journal of Immunology·S GonzálezR Silva
Oct 26, 2011·Proceedings of the National Academy of Sciences of the United States of America·John B RobbinsMark A Miller
Apr 27, 2000·The Pediatric Infectious Disease Journal·A J Pollard, M Levin
Jan 5, 2002·Clinical and Diagnostic Laboratory Immunology·Tamara RodríguezOliver Pérez
Jun 29, 2002·Archives of Disease in Childhood·A J Pollard, E R Moxon
Sep 2, 2004·Paediatric Drugs·Jens U Rüggeberg, Andrew J Pollard
Nov 19, 2010·Bioanalysis·Neil RavenscroftChristopher Jones
Mar 21, 2013·Journal of Controlled Release : Official Journal of the Controlled Release Society·Qingrui HuangTao Hu
Jul 5, 2005·Expert Opinion on Investigational Drugs·R K Sood, A Fattom
Jun 1, 2012·Expert Opinion on Drug Discovery·Paolo CostantinoFrancesco Berti
Jun 3, 2015·Glycobiology·Omid Haji-GhassemiStephen V Evans
Feb 5, 2015·Clinical and Experimental Vaccine Research·Shee Eun LeeJoon Haeng Rhee
Aug 1, 1997·Revista de saúde pública·H I Requejo
Feb 7, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Concetta BeninatiGiuseppe Teti

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.